Trial · NCT03829462
Results by group104
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 104
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival | Irinotecan + Regorafenib (REGIRI) | 9 | 95% Confidence Interval 6.1 to 14.5 | Month | |
| Overall Survival | Regorafenib | 5.5 | 95% Confidence Interval 3.8 to 13.4 | Month | |
| Progression-free Survival (PFS) | Irinotecan + Regorafenib (REGIRI) | 3.6 | 95% Confidence Interval 2 to 4.2 | month | |
| Progression-free Survival (PFS) | Regorafenib | 1.9 | 95% Confidence Interval 1.8 to 2.1 | month | |
| Time to Deterioration | Irinotecan + Regorafenib (REGIRI) | 4.6 | 95% Confidence Interval 3.6 to 5 | month | |
| Time to Deterioration | Regorafenib | 2.1 | 95% Confidence Interval 1.4 to 3 | month | |
| Number of Participants With Disease Control Rate | Irinotecan + Regorafenib (REGIRI) | 20 | Participants | ||
| Number of Participants With Disease Control Rate | Regorafenib | 8 | Participants | ||
| Number of Patients With an Objective Response Rate | Irinotecan + Regorafenib (REGIRI) | 2 | Participants | ||
| Number of Patients With an Objective Response Rate | Regorafenib | 0 | Participants | ||
| Assessment of Adverse Events by Using the NCI-CTCAE Version 5.0 Scale (Grade Max Per Patient) | Irinotecan + Regorafenib (REGIRI) | Grade 1 | 4 | Participants | |
| Assessment of Adverse Events by Using the NCI-CTCAE Version 5.0 Scale (Grade Max Per Patient) | Regorafenib | Grade 1 | 2 | Participants | |
| Assessment of Adverse Events by Using the NCI-CTCAE Version 5.0 Scale (Grade Max Per Patient) | Irinotecan + Regorafenib (REGIRI) | Grade 2 | 13 | Participants | |
| Assessment of Adverse Events by Using the NCI-CTCAE Version 5.0 Scale (Grade Max Per Patient) | Regorafenib | Grade 2 | 8 | Participants | |
| Assessment of Adverse Events by Using the NCI-CTCAE Version 5.0 Scale (Grade Max Per Patient) | Irinotecan + Regorafenib (REGIRI) | Grade 3 | 9 | Participants | |
| Assessment of Adverse Events by Using the NCI-CTCAE Version 5.0 Scale (Grade Max Per Patient) | Regorafenib | Grade 3 | 21 | Participants | |
| Assessment of Adverse Events by Using the NCI-CTCAE Version 5.0 Scale (Grade Max Per Patient) | Irinotecan + Regorafenib (REGIRI) | Grade 4 | 4 | Participants | |
| Assessment of Adverse Events by Using the NCI-CTCAE Version 5.0 Scale (Grade Max Per Patient) | Regorafenib | Grade 4 | 1 | Participants | |
| Assessment of Adverse Events by Using the NCI-CTCAE Version 5.0 Scale (Grade Max Per Patient) | Irinotecan + Regorafenib (REGIRI) | Grade 5 | 3 | Participants | |
| Assessment of Adverse Events by Using the NCI-CTCAE Version 5.0 Scale (Grade Max Per Patient) | Regorafenib | Grade 5 | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03829462/results